Solid amorphous formulations for enhancing solubility and inhibiting Erlotinib crystallization during gastric-to-intestinal transfer. - Mugnier, L.; Espitalier, F.; Menegotto, J.; Bell, S.; Ré, M. I. (Pharmaceutical Development & Technology, 2023)